TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30624668

Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate 6 million IU (MIU) loading dose followed by 3 MIU every 8 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PIRRT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Colistin methanesulfonate
Number of subjects: 8
Study: 30624677

Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 141

Group type: COMPARATOR
Intervention: HIV-uninfected participants
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HIV-infected men
Number of subjects: 141

Group type: COMPARATOR
Intervention: HIV-uninfected men
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HIV group
Number of subjects: 141
Study: 30624827

Group type: EXPERIMENTAL
Intervention: Improved Informed Consent Process (IICP) involving viewing a video and participating in extended group discussions.
Number of subjects: 112

Group type: COMPARATOR
Intervention: HIV disclosed status
Number of subjects: 112
Study: 30624987

Group type: EXPERIMENTAL
Intervention: Patients with fibromuscular dysplasia
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hypertensive patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study: 30625462

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg
Number of subjects: 32
Study: 30625501

Group type: EXPERIMENTAL
Intervention: Patient portal invitation to visit a LCS interactive Web site
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Interactive Web site for screening eligibility
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Chest computed tomography
Number of subjects: 1000
Study: 30626191

Group type: EXPERIMENTAL
Intervention: Technology-based medication adherence support intervention (real-time adherence monitors linked to SMS text messages)
Number of subjects: 28
Study: 30626202

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in BAV patients
Number of subjects: 101

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation in TAV patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in both BAV and TAV patients
Number of subjects: 101
Study: 30626203

Group type: EXPERIMENTAL
Intervention: High pre-Tei (≥0.45)
Number of subjects: 824

Group type: COMPARATOR
Intervention: Normal pre-Tei (<0.45)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Post-Tei normal
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Post-Tei high
Number of subjects: 824
Study: 30626238

Group type: EXPERIMENTAL
Intervention: Ig20Gly
Number of subjects: 50
Study: 30626327

Group type: EXPERIMENTAL
Intervention: Hidden Markov Models (HMMs) applied to reassurance types from audio files of consultations.
Number of subjects: 0
Study: 30626372

Group type: EXPERIMENTAL
Intervention: Past 12-month discrimination, unemployment, lifetime intimate partner violence (IPV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lower educational attainment, past 12-month discrimination
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low annual household income, past 12-month discrimination
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Past 12-month discrimination
Number of subjects: 150

Group type: COMPARATOR
Intervention: Having a partner
Number of subjects: 150

Group type: COMPARATOR
Intervention: Greater resilience
Number of subjects: 150

Group type: COMPARATOR
Intervention: Resilience
Number of subjects: 150

Group type: COMPARATOR
Intervention: Higher age, greater resilience
Number of subjects: 150
Study: 30626404

Group type: EXPERIMENTAL
Intervention: In-hospital ECG recording
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: IV access established during transportation
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Good communication with stroke centres
Number of subjects: 520
Study: 30626544

Group type: EXPERIMENTAL
Intervention: HDL-C sub-particles
Number of subjects: 304

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 304
Study: 30626567

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction during IV procedures
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard of Care (SOC) distraction during IV procedures
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 25
Study: 30626633

Group type: EXPERIMENTAL
Intervention: hs-cTnT at presentation >14 ng/L
Number of subjects: 3828

Group type: EXPERIMENTAL
Intervention: hs-cTnT at presentation >52 ng/L
Number of subjects: 3828

Group type: EXPERIMENTAL
Intervention: Initial cTn concentrations alone and in combination with early changes
Number of subjects: 3828

Group type: EXPERIMENTAL
Intervention: Serial sampling
Number of subjects: 3828
Study: 30626655

Group type: EXPERIMENTAL
Intervention: Functional measures (a-NSAA, MFM-20, timed function tests, 6MWT, Brooke scale, Jebsen test, manual muscle testing, hand-held dynamometry, ACTIVLIM questionnaire)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: a-NSAA score
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 6MWT
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 10-meter walk test
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: MFM domain 3, wrist flexion strength, pinch grip
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Progression rates
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Power calculations
Number of subjects: 193
Study: 30626746

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine daily for 7 days
Number of subjects: 10
Study: 30628574

Group type: EXPERIMENTAL
Intervention: Malaria prevention strategies in pregnancy
Number of subjects: 1
Study: 30629045

Group type: EXPERIMENTAL
Intervention: High physical activity (PA) tertile
Number of subjects: 4034

Group type: EXPERIMENTAL
Intervention: Low physical activity (PA) tertile
Number of subjects: 4034

Group type: EXPERIMENTAL
Intervention: Hierarchical modeling
Number of subjects: 4034
Study: 30629195

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) for 2 weeks
Number of subjects: 124
Study: 30629202

Group type: EXPERIMENTAL
Intervention: Iron deficiency (sTfR >6.0 mg/L) in early pregnancy
Number of subjects: 2379

Group type: EXPERIMENTAL
Intervention: Replete iron status (sTfR <10th percentile) in early pregnancy
Number of subjects: 2379

Group type: EXPERIMENTAL
Intervention: Iron deficiency in late pregnancy
Number of subjects: 2379

Group type: EXPERIMENTAL
Intervention: Iron-replete status in late pregnancy
Number of subjects: 2379
Study: 30630356

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) in low-surgical risk patients (logES <10%)
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) in intermediate-surgical risk patients (logES 10%-20%)
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) in high-surgical risk patients (logES ≥20%)
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (TAVI) across all risk categories
Number of subjects: 1785
Study: 30630355

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30630358

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30630419

Group type: EXPERIMENTAL
Intervention: Upper Lip Bite Test (ULBT)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Modified Mallampati (MMT) classification
Number of subjects: 344
Study: 30630452

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside (IIM) 5% (Diafer®)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 198
Study: 30630502

Group type: EXPERIMENTAL
Intervention: 4 × 5 Gy of high-precision radiotherapy to the dominant symptomatic lesion and 4 × 7 Gy to the most aggressive part of the lesion using a simultaneous integrated boost technique.
Number of subjects: 34
Study: 30630632

Group type: EXPERIMENTAL
Intervention: Higher zBMI
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Low-grade inflammation (CRP >1.0 mg/L to <10.0 mg/L)
Number of subjects: 1607
Study: 30630885

Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo in combination with paclitaxel, carboplatin, and bevacizumab
Number of subjects: 1300
Study: 30630956

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U
Number of subjects: 715
Study: 30630975

Group type: EXPERIMENTAL
Intervention: Total body irradiation Level-1 (300 cGy)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Total body irradiation Level-2 (400 cGy)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Total body irradiation Level-3 (450 cGy)
Number of subjects: 77
Study: 30631299

Group type: EXPERIMENTAL
Intervention: Multi-Modality Brain Injury Assessments
Number of subjects: 0
Study: 30631878

Group type: EXPERIMENTAL
Intervention: Whole blood lead (BL) levels
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Stroop test (ST)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Digit-symbol test (DST)
Number of subjects: 339
Study: 30632302

Group type: COMPARATOR
Intervention: Control (1-min control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Obstructed breathing (1 min)
Number of subjects: 40
Study: 30632847

Group type: EXPERIMENTAL
Intervention: Asparaginase treatment
Number of subjects: 0
Study: 30633128

Group type: EXPERIMENTAL
Intervention: Chemotherapy with paclitaxel and a platinum compound
Number of subjects: 4739

Group type: EXPERIMENTAL
Intervention: Time to recurrence after initial chemotherapy
Number of subjects: 4739

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting survival after recurrence
Number of subjects: 4739

Group type: EXPERIMENTAL
Intervention: Second look laparotomy with complete pathologic response or intraperitoneal chemotherapy
Number of subjects: 4739
Study: 30633573

Group type: EXPERIMENTAL
Intervention: Entospletinib 400 mg BID
Number of subjects: 49
Study: 30634942

Group type: EXPERIMENTAL
Intervention: Afatinib (30 mg) as add-on to gemcitabine/cisplatin (80% standard dose)
Number of subjects: 9
Study: 30634955

Group type: EXPERIMENTAL
Intervention: Case Management (CM) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation process
Number of subjects: 0
Study: 30634988

Group type: EXPERIMENTAL
Intervention: Ambulatory group of DS patients (37 patients)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hospitalized group of DS patients (64 patients)
Number of subjects: 101
Study: 30635024

Group type: EXPERIMENTAL
Intervention: Very low energy diet (VLED) at 640 kcal/day for 12-16 weeks, followed by a gradual reintroduction of an energy-restricted diet.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Very low energy diet (VLED) at 640 kcal/day for 12-16 weeks.
Number of subjects: 41
Study: 30635165

Group type: EXPERIMENTAL
Intervention: Veliparib 40 mg BID with gemcitabine 400 mg/m² and daily IMRT
Number of subjects: 30
Study: 30635261

Group type: EXPERIMENTAL
Intervention: Healing Circles
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 250
Study: 30635336

Group type: EXPERIMENTAL
Intervention: Combination of palbociclib (75 mg) and paclitaxel (80 mg/m2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Palbociclib alone
Number of subjects: 27
Study: 30635409

Group type: EXPERIMENTAL
Intervention: High-definition white light (WL)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging with near focus (NBI-NF)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: WL with near focus (WL-NF)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Offline assessment by experienced endoscopists
Number of subjects: 230
Study: 30635495

Group type: EXPERIMENTAL
Intervention: Transitional care strategies provided by hospitals
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hospitals that met the TCM definition
Number of subjects: 41

Group type: COMPARATOR
Intervention: Stroke center certification, Magnet designation, and use of TCM billing codes
Number of subjects: 41
Study: 30636101

Group type: EXPERIMENTAL
Intervention: hfTENS device (Quell, NeuroMetrix, Inc.) used daily for 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 68
Study: 30636249

Group type: EXPERIMENTAL
Intervention: Furosemide stress test (FST) with a single dose of intravenous furosemide, 1.5 mg/kg at 3 h after allograft reperfusion
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Furosemide stress test (FST)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Urine neutrophil gelatinase-associated lipocalin (NGAL), resistive index (RI) of renal arteries, effective renal plasma flow (ERPF)
Number of subjects: 59
Study: 30636515

Group type: EXPERIMENTAL
Intervention: Mitral Annulus Calcium (MAC) score quartiles
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Mitral Annulus Calcium (MAC) score as a continuous variable
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Mitral Annulus Calcium (MAC) score quartile cutoffs
Number of subjects: 168
Study: 30636521

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Trans-fatty acids
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Animal MUFAs
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Plant MUFAs
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Marine omega-3 PUFAs
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: α-linolenic acid
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Replacement of 5% of energy from SFAs with plant MUFAs
Number of subjects: 521120

Group type: EXPERIMENTAL
Intervention: Replacement of 2% of energy from SFAs with linoleic acid
Number of subjects: 521120
Study: 30637118

Group type: EXPERIMENTAL
Intervention: Fish oil supplement with milk
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fish oil supplement with food
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fish oil supplement on an empty stomach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Frozen fish oil capsules prior to ingestion
Number of subjects: 60
Study: 30637134

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin therapy
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 2700
Study: 30637483

Group type: EXPERIMENTAL
Intervention: Higher degree of obesity
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Higher levels of IL-6
Number of subjects: 671
Study: 30637570

Group type: EXPERIMENTAL
Intervention: Severe OSAS
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Moderate OSAS
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mild OSAS
Number of subjects: 104
Study: 30637784

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) with reduced toxicity preparative regimen of busulfan (13.2 mg/kg) and fludarabine (175 mg/m2)
Number of subjects: 0
Study: 30638399

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg once daily
Number of subjects: 51
Study: 30638769

Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 27
Study: 30638822

Group type: EXPERIMENTAL
Intervention: WIC-eligible foods
Number of subjects: 2777

Group type: COMPARATOR
Intervention: WIC participation
Number of subjects: 2777
Study: 30638821

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) intake adjusted for energy intake, MAR, and baseline socioeconomic status
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Water/sugar-free beverage intake adjusted for energy intake, MAR, and baseline socioeconomic status
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: 100% juice intake
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Milk intake
Number of subjects: 720
Study: 30638856

Group type: EXPERIMENTAL
Intervention: Burosumab (0.8 mg/kg) via subcutaneous injection every 2 weeks for 64 weeks, with possible increase to 1.2 mg/kg based on serum phosphorus levels.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Burosumab treatment
Number of subjects: 13
Study: 30639779

Group type: EXPERIMENTAL
Intervention: CLDQ-NASH
Number of subjects: 1667
Study: 30640246

Group type: EXPERIMENTAL
Intervention: ENT surgical procedures
Number of subjects: 5572

Group type: COMPARATOR
Intervention: Non-ENT surgical procedures
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: History of snoring, recent upper respiratory tract infection, recent wheezing
Number of subjects: 5572

Group type: EXPERIMENTAL
Intervention: Age below 4.6 years and lower surgical volume thresholds (<20 cases/2 weeks)
Number of subjects: 5572
Study: 30640659

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (four incremental doses)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 49
Study: 30640706

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Systematic pelvic lymphadenectomy
Number of subjects: 300
Study: 30641227

Group type: EXPERIMENTAL
Intervention: Comprehensive molecular testing of nasopharyngeal and oropharyngeal swabs (NPS)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Routine diagnostic tests (blood and sputum culture, urine antigen detection)
Number of subjects: 199
Study: 30641478

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Emergency cesarean section
Number of subjects: 104

Group type: COMPARATOR
Intervention: Planned cesarean section
Number of subjects: 104

Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 104
Study: 30641498

Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) optimization using singular value decomposition and minimization of field anisotropy (FA).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor treating fields (TTFields) optimization.
Number of subjects: 0
Study: 30641533

Group type: EXPERIMENTAL
Intervention: Walking capacity measured by Six Minutes Walking Test (6MWT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Knee pain severity
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lower limb strength
Number of subjects: 48
Study: 30642285

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with 3 cycles of cisplatin and pemetrexed
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Metabolic responders on FDG-PET scan after chemotherapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Non-responders on FDG-PET scan after chemotherapy
Number of subjects: 25
Study: 30642290

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg IV every 4 weeks) and Tremelimumab (75 mg IV every 4 weeks for a total of 4 doses) with SBRT to 2-5 metastases
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Progression Free Survival (PFS)
Number of subjects: 35
Study: 30642302

Group type: EXPERIMENTAL
Intervention: Plain abdominal radiography (PAR)
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Admission to the private hospital ED
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 1997
Study: 30642372

Group type: EXPERIMENTAL
Intervention: Chiauranib 65 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chiauranib 50 mg/day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chiauranib (various doses from 10 to 65 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chiauranib
Number of subjects: 18
Study: 30642373

Group type: EXPERIMENTAL
Intervention: JS001 (anti-PD-1 antibody)
Number of subjects: 36
Study: 30642415

Group type: EXPERIMENTAL
Intervention: Amisulpride (6 weeks treatment)
Number of subjects: 22
Study: 30642537

Group type: EXPERIMENTAL
Intervention: Afatinib (first-line treatment, modified starting dose of ≤30 mg for 31.1% of patients, 40 mg starting dose for others)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg starting dose)
Number of subjects: 228
Study: 30642545

Group type: EXPERIMENTAL
Intervention: ASC plus vinorelbine
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: ASC plus mitomycin, vinblastine and cisplatin (MVP)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Active symptom control (ASC)
Number of subjects: 409
Study: 30642819

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg or 560 mg daily) + Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ibrutinib + Nivolumab
Number of subjects: 141
Study: 30643112

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin 92 mg/m² or cisplatin 7.5 mg/m² and doxorubicin 1.5 mg/m², repeated every 6 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: PIPAC procedures
Number of subjects: 2
Study: 30643152

Group type: EXPERIMENTAL
Intervention: ad hoc designed polychromatic-flowcytometry (PFC) Lyotube
Number of subjects: 50

Group type: COMPARATOR
Intervention: CellSearch system
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both counting procedures (PFC and CellSearch)
Number of subjects: 50
Study: 30643455

Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin (ADD group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tamoxifen (TAM group)
Number of subjects: 62
Study: 30644132

Group type: EXPERIMENTAL
Intervention: Sample enrichment recruitment methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate risk score (MRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical modeling of identified markers
Number of subjects: 0
Study: 30644585

Group type: EXPERIMENTAL
Intervention: Cangrelor as a bridge therapy
Number of subjects: 0
Study: 30644648

Group type: EXPERIMENTAL
Intervention: rs295137 in SPATS2L
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: rs7037276 in IL33
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: rs1342326 in IL33
Number of subjects: 591
Study: 30644817

Group type: EXPERIMENTAL
Intervention: Focused ultrasound-mediated hyperthermia for targeted drug delivery
Number of subjects: 10